A number of research firms have changed their ratings and price targets for Carbylan Therapeutics (NASDAQ: CBYL): 8/21/2015 – Carbylan Therapeutics was downgraded by analysts at Zacks from a “hold” rating to a “sell” rating. According to Zacks, “Carbylan Therapeutics, Inc. is a specialty pharmaceutical company which focused on the development and commercialization of combination […]
